arrow
E

Eva Havrdová

first faculty of medicine
H指数:82
被引数:4.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Erratum to “Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years” [Multiple Sclerosis and Related Disorders, Volume 67, November 2022, 104187]

勘误:“基于T2病灶评估疾病活动量在预测多发性硬化10年疾病进展中的应用”[多发性硬化及相关疾病,第67卷,2022年11月,104187]

2026-09-010
PRE
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study

富马酸博纳利司(ponesimod)在复发型多发性硬化患者中的长期安全性与有效性:来自OPTIMUM 3期研究5年长期扩展研究的结果

2026-03-250
OAAI
Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study

复发型多发性硬化患者接受克拉屈滨片治疗后认知和就业的稳定性:两年期IV期CLARIFY-MS研究

2026-03-100
OAAI
The gut microbiota composition is shaped by disease activity and individual treatment responses in patients with multiple sclerosis

肠道微生物群组成受多发性硬化症患者疾病活动度和个体治疗反应的影响。

2026-02-120
OAAI
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial

奥扎尼妥(ozanimod)在复发型多发性硬化中的长期安全性与有效性:DAYBREAK开放标签扩展试验的最终分析

2025-11-050
OA
Ocrelizumab transiently alters microbiota and modulates immune response depending on treatment outcome

奥瑞利珠单抗可暂时改变微生物群,并根据治疗结果调节免疫反应

2025-10-310
OAAI
Serum bilirubin concentrations and their association with clinical and radiological outcomes in multiple sclerosis: A large cohort study

血清胆红素浓度及其与多发性硬化临床和影像学结局的关联:一项大型队列研究

2025-09-220
PREAI
Persistent progression independent of relapse activity in multiple sclerosis

多发性硬化中与复发活动无关的持续性进展

2025-08-210
OAAI
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

造血干细胞移植与免疫重建疗法在复发型多发性硬化中的比较

Brain
IF11.7
2025-08-040
PRE
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

基于真实世界常规临床数据的个性化联邦学习在预测多发性硬化致残进展中的应用

2025-07-240
OAAI
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials

奥扎尼妥单抗治疗复发型多发性硬化患者的脑萎缩及其与长期残疾和认知功能的关系:来自III期和开放标签扩展试验的结果

2025-07-230
PRE
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial

Ponesimod作为添加治疗在活动性复发多发性硬化患者中的应用(POINT):一项III期、随机、安慰剂对照临床试验

2025-07-130
PRE
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

四年之后:MSBase妊娠、新生儿结局及女性健康登记册(2020–2024)中报告的妊娠与分娩结局

2025-07-070
PRE
Explainable time-to-progression predictions in multiple sclerosis

多发性硬化症可解释的进展时间预测

2025-05-010
PRE